Anbio Biotechnology to Showcase Cutting-Edge Diagnostic Solutions at 2025 Medlab Middle East

January 22, 2025 04:08 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

DUBAI, UAE , Jan. 21, 2025 /PRNewswire/ -- Anbio Biotechnology ("Anbio"), a global leader in in-vitro diagnostic technologies, is excited to announce its participation in the 2025 Medlab Middle East exhibition, taking place from 3rd to 6th February at the Dubai World Trade Centre. The event is one of the region's largest and most important medical and laboratory equipment trade shows, bringing together leading manufacturers, distributors, and healthcare professionals from around the globe.

Anbio Biotechnology's booth Z1.H50 at 2025 Medlab Middle East
Anbio Biotechnology's booth Z1.H50 at 2025 Medlab Middle East

Anbio Biotechnology will be showcasing a range of its latest Point-of-Care Testing (POCT) products at Booth Z1.H50. These products include:

  • Dry Chemiluminescence Immunoassay System (Dry CLIA)
  • Immunofluorescence System (FIA)
  • Dry Biochemistry System
  • Colloidal Gold Rapid Tests

The company's participation aims to provide healthcare professionals, medical device distributors, and patients in the Middle East, Africa, and Europe with fast, reliable, and cost-effective in-vitro diagnostic solutions that enhance healthcare outcomes.

Anbio's Featured Products at Medlab Middle East:

  • Dry Chemiluminescence Immunoassay System

The innovative dry chemiluminescence immunoassay system utilizes lyophilized reagents to enhance stability, reduce liquid reagent volume, and improve temperature resistance for room-temperature storage and transport. Compatible with nearly 70 reagents, it covers applications like coagulation, thrombosis, cancer markers, and hormone testing, ensuring reliable results across various clinical settings.

  • Immunofluorescence System

Ideal for rapid and precise detection, this immunofluorescence system is a powerful tool for Point-of-Care Testing (POCT). It supports 85 test parameters and is equipped with a built-in battery, allowing up to 8 hours of continuous testing without an external power source. Its versatility makes it suitable for various environments, including laboratories, ambulances, and pharmacies, ensuring reliable diagnostics wherever needed.

  • Dry Biochemistry System

The innovative dry biochemistry system ensures simplicity, efficiency, and reliability in various tests, particularly in emergency settings. It utilizes dry reagent strips, with one strip dedicated to each patient, and supports whole blood testing for most assays. The reagents can be stored and transported at room temperature. Offering quick and accurate biochemistry quantification, results are available in as little as 40 seconds, making it the ideal solution for fast-paced environments.

  • Colloidal Gold Rapid Tests

These tests provide a quick, easy-to-read, and reliable solution for detecting a variety of infections and conditions, offering fast results for better decision-making in patient care. With a wide range of available reagents, the system covers nearly 100 different test items, making it a cost-effective choice, particularly for large-scale screening.

About Medlab Middle East

Medlab Middle East is the region's premier event for laboratory and medical professionals, providing access to a vast array of the latest innovations in diagnostics, laboratory management, and medical technology. With thousands of visitors and exhibitors from around the world, it serves as a vital platform for networking, collaboration, and learning about emerging trends in healthcare diagnostics.

Anbio Biotechnology's innovative solutions at Medlab Middle East will demonstrate its commitment to advancing the future of diagnostic technology and improving healthcare delivery worldwide.

Visit us at Booth Z1.H50 at Medlab Middle East to learn more about our products and how they can transform your healthcare practices.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.